ONTOZRY 12.5 mg, tablet + 25 mg, film-coated tablet 28 tablets
Active ingredients: Cenobamate
Commercialized according to BDPMDispensing in France: Prescription only
Tablet and film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ONTOZRY 12,5 mg, comprimé + 25 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé et comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC aluminium de 28 comprimés (14x12,5 mg + 14x25 mg)
- Marketing authorisation holder
- ANGELINI PHARMA (ITALIE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 May 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69821184CIP73023003CIP133400930230039Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CÉNOBAMATEcomprimé 12,5 mg | 12,5 mg · un comprimé | SA |
| CÉNOBAMATEcomprimé 25 mg | 25 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.